Introduction
Amyloid is characterized by the pathological deposition of peptides and proteins in diverse tissues and organs, which interferes with normal tissue and organ function. It consists of misfolded, insoluble, toxic proteinaceous aggregates, which are oriented in a β-sheet structure [
1‐
3]. Immunoglobulin-light (AL) chain-derived amyloidosis is the most common amyloidosis in Europe and North America and represents a hematological disorder and manifests either systemically or locally. Localized AL amyloidosis is rare and may occur at different anatomical locations, including the respiratory and gastrointestinal tract [
4,
5]. Both systemic and localized AL amyloidosis are associated with a variety of plasmacytic-differentiated B cell lympho-proliferations. Systemic AL amyloidosis has been linked to a plasma cell dyscrasia, which either resembles a mild increased plasma cell number in the bone marrow [
6], an overt plasma cell myeloma, or a lymphoplasmacytic lymphoma (M. Waldenström) [
7,
8]; the latter all representing systemic diseases. Recent literature describes smaller cohorts and case reports of localized AL amyloidosis, which are associated with localized plasmacytic-differentiated B cell lympho-proliferations [
4,
9‐
12], where the exact classification of the plasmacytic-differentiated B cell neoplasia often remains an unsolved issue.
We report here on a prospective series of 29 patients with AL amyloidosis, who presented with a sparse lymphoplasmacytic infiltrate within or surrounding the amyloid deposits, some of which we subsequently classified as a “AL amyloidosis with a localized B-cell neoplasia of undetermined significance”.
Materials and methods
Patient cohort and study design
Before the study was started, a set of histological (H&E, Congo red), immunohistochemical (antibody panels; see below), and molecular pathological (λ- and κ-light chain in situ-hybridization, IGH-PCR, MYD88-genotype) analyses were defined which should be applied in every case with histological and immunohistochemical (λ- and κ-light chain immunostaining) evidence of a putative clonal lymphoplasmacytic infiltrate. The study was then started in 2015, and until 2017, we collected 29 cases during routine diagnostics of the tertiary referral center (Amyloid Registry Kiel) with biopsy-proven AL amyloidosis and a sparse lymphoplasmacytic infiltrate surrounding the amyloid deposits. Biopsy site, patient age, and gender were documented.
Histopathology
All specimens had been fixed in formalin and embedded in paraffin (FFPE). Serial sections were cut from each paraffin block and stained with hematoxylin and eosin and Congo red. Amyloid was diagnosed when a typical green-yellow-orange birefringence was found in cross-polarized light in Congo red-stained sections.
Immunohistochemistry
Immunohistochemical classification of amyloid was carried out and had been validated as described in detail elsewhere [
13‐
17].
The lymphoplasmacytic infiltrate and the light chain restriction of the plasma cells were characterized using commercially available antibodies directed against CD5, CD10, CD20, CD23, CD56 and Cyclin D1, and in situ hybridization
κ and
λ light chain as listed in Supp. Table
1. Plasma cells were interpreted as
κ light chain restricted when the ratio between
κ- and
λ positive plasma cells was above 8:1. The
λ light chain restriction was reported, when
λ was expressed in a higher proportion of plasma cells compared to
κ positive plasma cells [
16].
DNA extraction and analysis of clonal immunoglobulin rearrangements
Genomic DNA was extracted from FFPE tissue with QIAamp DNA Mini Kit (Qiagen GmbH, Hilden, Germany) according to the manufacturer’s instructions. DNA was used as template for amplification of immunoglobulin heavy chain (
IGH) and light chain (
IGK) gene rearrangements according to the BIOMED-2 multiplex protocol [
18]. PCR products were subjected to GeneScan analysis for characterization of Ig gene rearrangement patterns on an ABI 3500 genetic analyzer (Applied Biosystems, Darmstadt, Germany). Data analysis was performed with GeneMapper Software v4.1. Interpretation of GeneScan results was performed according to standard guidelines [
19].
MYD88 L265P mutation analysis
A 76 basepair-fragment spanning codon 265 of the human MYD88 gene was amplified from genomic DNA by PCR using the primers MYD88-F2 (5′-gcaggtgcccatcagaagc-3′) and MYD88-R2 (5′-acctcaggatgctggggaact-3′). The amplified PCR products were controlled by agarose gel electrophoresis and directly sequenced by pyrosequencing on a PyroMark Q24 sequencer (Qiagen) using the sequencing primer MYD88-S1 (5′-cccatcagaagcgac-3′). The sequencing results were analyzed using the PyroMark Q24 software. The detection limit of the applied assay accounts for 5% tumor DNA.
Clinical data
Clinical data were obtained by interrogation of the treating physicians using a standardized questionnaire, focusing on the following items: were the amyloid depositions systemically or localized; was the patient suffering from a systemic lymphoma; and was there a monoclonal gammopathy in the serum immunofixation electrophoresis?
Disease classification
Systemic disease was assumed, when systemic amyloidosis was diagnosed clinically and/or when there was evidence for lymphoma infiltration in the bone marrow and/or if the medical history of the patient showed evidence for a systemic lymphoma.
A localized disease was signed out in patients with evidence of local amyloid deposits associated with a clonal plasma cell infiltration without clinical data and/or negative clinical staging were designated as: “AL amyloidosis with a localized B-cell neoplasia of undetermined significance (AL-LBN)”. All cases are categorized in Table
1 and Supp. Table
2. Cases with systemic disease or missing clonality of the lymphoplasmacytic infiltrate are categorized as “others” in Supp. Table
2.
Table 1
Characteristics of a cohort of 29 patients with AL amyloidosis and an overt lymphoplasmacytic infiltrate (for further details see Suppl. Table
2,
MgZl, marginal zone lymphoma;
n.a., not available,
AL-LBN,
AL amyloidosis with localized B cell neoplasia of undetermined significance)
1 | F | 62 | Orbita | ALκ | n.a. | n.a. |
AL-LBN
|
2 | M | 68 | Epipharynx | ALκ | l |
n
|
AL-LBN
|
3 | F | 56 | Lung | ALκ | n.a. | n.a. |
AL-LBN
|
4 | F | 57 | Lung | ALκ | l | n.a. |
AL-LBN
|
5 | M | 63 | Lung | ALκ | n.a. | n.a. |
AL-LBN
|
6 | M | 56 | Lung | ALλ | n.a. | n.a. |
AL-LBN
|
7 | F | 68 | Lung | ALλ | n.a. | n.a. |
AL-LBN
|
8 | M | 37 | Lung | ALλ | n.a. | n.a. |
AL-LBN
|
9 | M | 80 | Lung | ALλ | l |
n
|
AL-LBN
|
10 | F | 71 | Lung | ALλ | l | n.a. |
AL-LBN
|
11 | M | 73 | Lung | ALλ | n.a. | n.a. |
AL-LBN
|
12 | M | 69 | Lung | ALλ | n.a. | n.a. |
AL-LBN
|
13 | F | 72 | Lung | ALλ | n.a. | n.a. |
AL-LBN
|
14 | M | 74 | Skin | ALλ | l | n.a. |
AL-LBN
|
15 | M | 70 | Skin | ALλ | l |
n
|
AL-LBN
|
16 | M | 67 | Lymph node | ALλ | l | n.a. |
AL-LBN
|
17 | F | 38 | Lymph node | ALλ | l |
n
|
AL-LBN
|
18 | M | 57 | Ureter | ALλ | l |
n
|
AL-LBN
|
19 | M | 36 | Bladder | ALλ | l |
n
|
AL-LBN
|
20 | M | 72 | Bladder | ALλ | l |
n
|
AL-LBN
|
21 | F | 66 | Soft tissue | ALλ | n.a. | n.a. |
AL-LBN
|
22 | M | 82 | Colon, mesenterium, lymph node | ALλ | n.a. | n.a. |
AL-LBN
|
23 | F | 66 | N. ischiadicus | ALλ | n.a. | n.a. |
AL-LBN
|
24 | M | 67 | Lung | ALκ | l | y (suspicious for MgZL) | Systemic MgzL with associated tumorous ALκ amyloidosis |
25 | M | 60 | Lung | ALκ | l |
n
| ALκ amyloidosis with an associated predominant κ light chain expressing plasma cell population without evidence for clonality |
26 | M | 77 | Lung | ALλ | s |
y
| Systemic B-cell lymphoma with associated ALλ amyloidosis |
27 | M | 56 | Lymph node | ALκ | s | y (no diagnosis) | Systemic B-cell lymphoma with associated ALκ amyloidosis |
28 | F | 64 | Soft tissue | ALκ | l | y | Systemic plasmacytic-differentiated MgzL |
29 | M | 81 | Bone marrow, small bowel | ALκ | n.a. |
y
| Plasma cell myeloma and vascular and interstitial ALκ amyloidosis |
Discussion
The current WHO-classification of Tumors of Hematopoietic and Lymphoid Tissue 2017 [
6] classifies localized plasmacytic-differentiated B cell lymphoproliferations (e.g., in the skin, in the stomach, and in the salivary glands) as plasmacytic-differentiated marginal zone lymphomas, presupposing that a small B cell component is detectable within the biopsy specimen. Some authors claim that plasmacytic-differentiated marginal zone lymphomas have to be classified as pure plasma cell neoplasms, because they exhibit the immunophenotype of plasma cells rather than the immunophenotype of mature B cells in flow cytometry analysis [
20]. The question whether a relatively small B cell component in localized amyloidosis is part of the neoplastic clone or not is currently unknown, and the classification of a lymphoproliferation associated with localized AL amyloidosis is an unsolved issue. The main challenge is the differentiation between a pure localized plasmacytic-differentiated B cell lymphoma and a secondary infiltration by a systemic plasmacytic-differentiated B cell lymphoma.
Our study on a cohort of 29 patients with tumor-like AL amyloidosis showed a concomitant light chain restricted and predominantly molecularly clonal plasma cell population. Considering the clinical presentation, most of the herein analyzed cases presented as localized processes, in which a sparse local clonal plasmacytic infiltration causes a localized amyloid deposition within the tissue in an otherwise healthy patient without overt lymphoma. The final classification as a localized disease is solely possible ruling out a secondary infiltration by an underlying systemic plasmacytic-differentiated B cell lymphoma by appropriate staging as proposed for comparable entities like primary cutaneous lymphomas [
21‐
23].
In our cohort, AL
λ amyloid (59%) was slightly more prevalent than AL
κ amyloid (41%). The type of amyloid was 100% concordant with the detected light chain in the plasma cells. A clonal Ig-gene or
κ-light chain rearrangement was found in 23 patients. Four (14%) cases presented with an unambiguous light chain restricted plasma cell population without detectable clonal Ig-rearrangement. Putative explanations might be that the underlying clone was undetectable by the used primer systems due to somatic hypermutation in the Ig-gene locus, as it has been described in follicular lymphomas [
24], or the underlying clone was undetectable due to pauci-cellularity. Collectively, we identified 27 (93%) cases with an AL amyloidosis and an associated light chain restricted and predominantly molecularly clonal plasma cell population.
The accompanying lymphoplasmacytic infiltrate revealed a marginal zone-immunophenotype of the B cells in all cases. This finding excluded the diagnoses of a plasmacytic-differentiated chronic lymphocytic leukemia (CD5 and CD23 co-expression) [
25], rare variants of plasmacytic-differentiated follicular lymphoma (germinal center immunophenotype) [
26,
27], and a plasmacytic-differentiated mantle cell lymphoma (Cyclin D1 expression) [
28,
29].
Further, we were unable to find evidence for a lymphoplasmacytic lymphoma (M. Waldenström) using
MYD88-genotyping, since we found only a single case (no. 16; Supp. Table
2) exhibiting a
MYD88L265P-mutation. The patient presented with local κ-light chain AL amyloidosis in the lymph node and an associated κ-light chain restricted and molecularly clonal plasma cell population. Eighty-six to 100% of lymphoplasmacytic lymphomas harbor the
MYD88L265P-mutation [
30‐
33]. Further, 10–87% of IgM monoclonal gammopathy of undetermined significance (MGUS) shows the
MYD88L265P-mutation [
30‐
35]. Finally, the most likely differential diagnoses in our
MYD88L265P-mutated case are either a secondary infiltration of the lymph node by a lymphoplasmacytic lymphoma (M. Waldenström) or an IgM-MGUS. Unfortunately, data on clinical presentation and serum immunofixation electrophoresis were unavailable and no final diagnosis could be reached in this case.
In consideration of the additional clinical information, five patients (case no. 24, no. 26, no. 27, no. 28, no. 29) suffered from a systemic lymphoma, and one patient (case no. 25) presented with an ALκ amyloidosis with an associated predominant κ-light chain expressing plasma cell population without evidence for clonality. With regard to the remaining 23 (79%) cases, which had a light chain-restricted lymphoplasmacytic infiltrate without evidence of a systemic lymphoma and systemic amyloidosis, there are two open differential diagnoses: a localized plasmacytic-differentiated marginal zone lymphoma and a pure plasma cell-derived neoplasia. For the diagnosis of a plasmacytic-differentiated marginal zone lymphoma, we missed the more extended sheet-like infiltrate of a small B cell component, which was generally sparse in our cohort. For the diagnosis of an extramedullary plasmacytoma, we missed sheets of neoplastic plasma cells.
We believe that the herein described light chain restricted clonal plasma cell population is more appropriately described with the proposed term “
AL-LBN”, sharing features with MGUS in the bone marrow as described in the current WHO-classification of Tumors of Hematopoietic and Lymphoid Tissue 2017 [
6].
Our study results point out that the final diagnosis of an AL-LBN presumes a detailed elaboration of the following decision tree by answering the given questions: (1) Is there evidence for clonality of the lymphoplasmacytic infiltrate; (2) are the amyloid deposits localized or systemically; (3) is there evidence for a systemic lymphoma; and (4) is the final disease classification according to the histological pattern, i.e., (a) localized extranodal plasmacytic-differentiated marginal zone lymphoma (histological pattern: sheets of clonal B cells and intermingled clonal plasma cells), (b) localized extramedullary plasmacytoma (histological pattern: sheets of mature clonal plasma cells), or (c) AL-LBN (histological pattern: sparse lymphatic infiltrate and sparse clonal plasma cells)?
In view of the proposed
AL-LBN, we believe that the classification of the underlying disease of AL amyloidosis can be amended [
3]. Table
2 outlines in detail, which different forms of plasmacytic-differentiated B cell neoplasms are potentially causing either localized or systemic amyloidosis. Systemic AL amyloidosis may be associated with a systemic clonal plasma cell population in the bone marrow either resembling a frank multiple myeloma or a plasmacytic-differentiated B cell lymphoma [
7,
36,
37]. Localized AL amyloidosis may be associated with a localized clonal plasma cell population either resembling a plasmacytoma, a localized plasmacytic-differentiated B cell lymphoma (different possible subtypes), or a clonal infiltrate not meeting the criteria of a plasmacytic-differentiated marginal zone lymphoma or an extramedullary plasmacytoma, i.e.,
AL-LBN.
Table 2
Systematic delineation of the different presentation forms of AL amyloidosis
AL amyloid-deposition | Systemic | Systemic | Systemic | Systemic | Localized | Localized | Localized | Localized |
Histology of lympho-plasmacytic infiltrate | Intermingled reactive B-cells possible infiltration of densely packed tumor forming plasma cells often with a more immature appearance | Variable dense B-cell infiltrate with a plasma cell component | Variable dense B-cell infiltrate with a plasma cell component | CLL: Diffuse infiltration of small lymphocytes | Intermingled reactive B-cells possible predominant infiltration of densely packed tumor forming mature plasma cells | Variable dense B cell infiltrate with a plasma cell component | Intermingled single or cluster forming B cells, predominantly loosely packed infiltrating plasma cells | Unspecific inflammatory infiltrate without evidence of clonality |
Immunopheno-type of B cells | Reactive B-cells | CD20+; CD23, CD5, CD10 and Cyclin D1 negative | CD20+; CD23, CD5, CD10 and Cyclin D1 negative | CLL: CD20+, CD23+, CD5+ | Reactive B-cells | CD20+; CD23, CD5, CD10 and Cyclin D1 negative | CD20+; CD23, CD5, CD10 and Cyclin D1 negative | Reactive B-cells |
Immunopheno-type of plasma cells | CD20, CD23, CD5, CD10 negative. Occasionally Cyclin D1+ and CD56+, light chain restriction. | CD20, CD23, CD5, CD10 and Cyclin D1 negative and light chain restricted | CD20, CD23, CD5, CD10 and Cyclin D1 negative and light chain restricted | CD20, CD23, CD5, CD10, Cyclin D1 negative and light chain restriction. | CD20, CD23, CD5, CD10 and Cyclin D1 negative and light chain restriction | CD20, CD23, CD5, CD10 and Cyclin D1 negative and light chain restriction | CD20, CD23, CD5, CD10 and Cyclin D1 negative and light chain restriction | Polytypic |
Genotype of neoplastic cells | Often Cyclin D1 and occasionally MYC rearrangements | Occasionally t(14;18)(q32;q21) | MYD88 mutation (> 90%) | CLL: No specific genetic markers | Lack of Cyclin D1 translocation, lack of MYC rearrangement | Occasionally t(14;18)(q32;q21) t(11;18)(21;q21) | Unknown | No aberrations |
Clinics/staging | Evidence for systemic plasma cell myeloma (bone marrow involvement) | Evidence for systemic lymphoma e.g. bone marrow involvement, lymphadenopathy | Bone marrow involvement mandatory, loose clusters of lymphocytes and plasma cells with intermingled mast cells | Systemic involvement e.g. bone marrow involvement, lymphadenopathy or end organ involvement | No evidence for systemic plasma cell myeloma (no bone marrow involvement) | No evidence for systemic lymphoma (no bone marrow involvement, no lymphadenopathy) | No evidence for systemic lymphoma (no bone marrow involvement, no lymphadenopathy) | No evidence for systemic lymphoma (no bone marrow involvement, no lymphadenopathy) |
Monoclonal gammopathy* | Measurable | Measurable | Measurable (IgM) | Measurable | Negative or weakly positive | Negative or weakly positive | Negative or weakly positive | negative |
Localized AL amyloidosis with a localized clonal plasma cell population has been described in single case reports and in smaller cohorts [
11,
12,
38,
39]. Table
3 provides an overview of the literature with larger case series. Thompson et al. [
43] presented 11 cases of laryngeal AL amyloidosis and a concomitant sparse lymphoplasmacytic infiltrate with a reactive distribution pattern. None of the cases had evidence of a systemic plasmacytic-differentiated B cell lymphoma. Clonality was demonstrated by the light chain restriction of the plasma cells in 3/11 cases, which were subsequently categorized as localized AL amyloidosis with an associated lymphoplasmacytic disorder within the spectrum of marginal zone lymphomas. Ryan et al. [
9] described 20 cases of diverse anatomical origin with AL amyloidosis and an associated light chain restricted lymphoplasmacytic infiltrate, which was designated to be within the spectrum of extranodal marginal zone lymphomas. Two histological patterns were described: Firstly, samples that presented with a dense lymphoplasmacytic infiltrate with sparse amyloid deposits and, secondly, those which presented with tumorous amyloid deposits with a surrounding sparse lymphoplasmacytic infiltrate. Furthermore, clinico-pathological characteristics concerning the distribution pattern of the lymphoma and amyloid deposits were given. Molecular analyses, e.g., Ig-rearrangement analysis, were done only in two cases. Walsh et al. [
42] presented ten cases obtained from the skin with a localized AL amyloidosis and an associated light chain restricted plasma cell population, without evidence of a systemic involvement. Two patterns of AL amyloidosis were described: Firstly, systemic amyloidosis with an additional systemic B cell lymphoma and, secondly, localized AL amyloidosis with a localized B cell lymphoma, which was proposed to be within the spectrum of cutaneous marginal zone lymphomas. Ig-rearrangement analyses were not done in any of the cases. Single case reports and studies with smaller cohorts present localized AL amyloidosis with an associated light chain restricted plasma cell population at different anatomical sites [
12,
38,
39]. In all these studies, molecular analyses and assessment of the light chain restriction of the plasma cells have been carried out inconsistently or only in few cases, and a precise classification of the concomitant clonal plasma cell population, especially focusing on the differentiation between an extremely plasmacytic-differentiated marginal zone lymphoma and a pure plasma cell neoplasia, is largely missing (Table
3).
Table 3
Review of the literature
| 18 | Lung | - Variable degree of lymphoplasmacytic infiltrate particularly arranged in a reactive like pattern - No further subtyping of the B-cells | Monotypic 14/18 (78%) κ predominant, additional staining for heavy chain expression | 6/12 (59%) clonal | - MGUS 3/12 (25%; SPEP) - None (n = 14) t(14;18)(q32;q21) - Mass spectroscopy: co-deposition of heavy and light chains in localized AL amyloidosis | ND | - None of the patients developed systemic amyloidosis - 6/14 (43%) had recurrence (either MgzL or amyloidosis) | Lymphoplasmacytic disorder within the spectrum of MgzL |
| 11 6/11 NA 5/11 primary ML: either MgzL or CLL | Lung | Primary ML: all cases with a predominant infiltrate of small B-cells | 0/6 cases light chain restriction in NA 4/5 light chain restriction in ML (2/5 κ; 2/5λ | ND | ND | ND | ND | No statement about the further classification of the infiltrate |
| 6 primary pulmonary MgzL with secondary pulmonary amyloidosis | Lung | All cases presented with dense lymphoplasmacytic infiltrate | 3/3 κ | ND | 0/6 MGUS (SPEP) | 5/6 without evidence of lymphoma | - 2/6 dead (one with progress to DLBCL) - 4/6 alive | Lymphoplasmacytic disorder within the spectrum of MgzL |
| 10 | Skin | All cases with predominant amyloid deposits and a sparse lymphoplasmacytic infiltrate | 7/10 κ 3/10 λ | ND | ND | All except one no evidence of lymphoma | - 4/10 local recurrence | Lymphoplasmacytic disorder within the spectrum of MgzL |
| 20 | Diverse anatomical sites | 8/20 dense B-cell infiltrate (marginal zone immunophenotype) with sparse amyloid deposits 12/20 with dominant amyloid deposits with a sparse lymphoplasmacytic infiltrate | 12/19 λ 7/12 κ shown either by FACS analysis or by in situ hybridisation or by IHC | 2/2 clonal | - 3/11 negative- 8/11 IgM or IgG MGUS (SPEP) | 1/5 MgzL lymphoma | - 7/15 AWED - 6/15 AWD - 1 alive (without information) - 1 dead | Lymphoplasmacytic disorder within the spectrum of MgzL |
| 11 | Larynx | Predominant amyloid deposits with sparse lymphoplasmacytic infiltrate | 2/11 κ 1/11 λ 7/11 no light chain restriction | ND | ND | ND | - 3/11 AWED - 1/11 AWRD - 5/11 DWED - 2/11 DWD | Lymphoplasmacytic disorder within the spectrum of MgzL |
Current study | 29 | Diverse anatomical sites | All cases with predominant amyloid deposits and a sparse lymphoplasmacytic infiltrate, B-cells were arranged in a reactive-like pattern | 12/29 κ 17/29 λ | - 23/29 clonal - 5/29 polyclonal - 1/29 no amplification product | - 2/17 IgGκ (SPEP) - 2/17 systemic amyloidosis | 3/17 systemic lymphoma | - 9/17 alive - 2/17 DWED | AL-LBN |
Further, molecular analyses are warranted to differentiate between an extremely plasmacytic-differentiated localized extranodal marginal zone lymphoma and a pure plasma cell neoplasia to shed further light on the diverse etiologies and histoanatomical manifestations of AL amyloidosis.
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.